1. World Cancer Report 2014. World Health Organization. 2014.
  2. Howlader N., et al. SEER Cancer Statistics Review, 1975-2013. Natl. Cancer Inst. 2016.
  3. Groome P.A., et al. The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. J. Thorac. Oncol. 2007. Vol.2, №8, P. 694-705.
  4. Alberg A.J., Brock M. V, Samet J.M. Epidemiology of lung cancer: looking to the future. J. Clin. Oncol. 2005. Vol.23, №14, P. 3175-3185.
  5. Kyriakoudes L.M., Schiebinger L., Reid W. Historians’ testimony on “common knowledge” of the risks of tobacco use: a review and analysis of experts testifying on behalf of cigarette manufacturers in civil litigation. Tob. Control. BMJ Publishing Group Ltd, 2006. Vol.15, Suppl 4, P. iv107-16.
  6. Malhotra J., et al. Risk factors for lung cancer worldwide. Eur. Respir. J. 2016. Vol.48, №3, P. 889-902.
  7. Silvestri G.A., et al. Methods for Staging Non-small Cell Lung Cancer. Chest. 2013. Vol.143, №5, P. e211S-e250S.
  8. Travis W.D. WHO classification of tumours of the lung, pleura, thymus and heart. Int. Agency Res. Cancer. 2015.
  9. Amin M.B., et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA. Cancer J. Clin. Vol.67, №2, P. 93-99.
  10. Fukuoka M., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. American Society of Clinical Oncology, 2011. Vol.29, №21, P. 2866-2874.
  11. Lindeman N.I., et al. Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline from the College of American Pathologists, International
  12. Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Thorac. Oncol. Vol.8, №7, P. 823-859.
  13. Ricciuti B., et al. Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther. Adv. Med. Oncol. SAGE Publications, 2017. Vol.9, №6, P. 387-404.
  14. Yang C.-F.J., et al. Use and Outcomes of Minimally Invasive Lobectomy for Stage I Non-Small Cell Lung Cancer in the National Cancer Data Base. Ann. Thorac. Surg. 2016. Vol.101, №3, P. 1037-1042.
  15. McKenna R.J., Houck W., Fuller C.B. Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases. Ann. Thorac. Surg. 2006. Vol.81, №2, P. 421-426.
  16. Flores R.M., et al. Lobectomy by video-assisted thoracic surgery (VATS) versus thoracotomy for lung cancer. J. Thorac. Cardiovasc. Surg. 2009. Vol.138, №1, P. 11-18.
  17. Paul S. et al. Long term survival with thoracoscopic versus open lobectomy: propensity matched comparative analysis using SEER-Medicare database. BMJ. 2014. Vol.349.
  18. Амиралиев А.М. и соавт. Федеральные клинические рекомендации по диагностике и лечению больных раком легкого. Москва, 2014.
  19. Ettinger D.S., et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. Harborside Press, LLC, 2017. Vol.15, №4, P. 504-535.
  20. Cullen M. “Best supportive care” has had its day. Lancet. Oncol. Elsevier, 2001. Vol.2, №3, P. 173-175.

Примеры итоговых тестов и ситуационных задач

Тесты по Онкологии с ответами для врачей

Тест по онкологии с ответами, Экзамены из Биология

Персонализированный подход к терапии немелкоклеточного рака легкого

Сеченовский Университет

Ханты-Мансийская государственная медицинская академия

КГБУЗ Онкологический диспансер г. Комсомольск-на-Амуре